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The presence of protein aggregates is commonly believed to be an important risk factor for immuno-
genicity of therapeutic proteins. Among all types of aggregates, dimers are relatively abundant in most
commercialized monoclonal antibody (mAb) products. The aim of this study was to investigate the
immunogenicity of artificially created mAb dimers relative to that of unstressed and stressed mAb
monomers. A monoclonal murine IgG1 (mIgG1) antibody was exposed to low pH, elevated temperature,
or UV irradiation to induce dimerization. Dimers and monomers were purified via size-exclusion
chromatography. Physicochemical analysis revealed that upon all stress conditions, new deamidation
or oxidation or both of amino acids occurred. Nevertheless, the secondary and tertiary structures of all
obtained dimers were similar to those of unstressed mIgG1. Isolated dimers were administered subcu-
taneously in Balb/c mice, and development of antidrug antibodies and accumulation of follicular T helper
cells in draining lymph nodes and spleens were determined. None of the tested dimers or stressed
monomers were found to be more immunogenic than the unstressed control in our mouse model. In
conclusion, both dimers and monomers generated by using 3 different stress factors have a low
immunogenicity similar to that of the unstressed monomers.
© 2019 American Pharmacists Association
®
. Published by Elsevier Inc. All rights reserved.Introduction
Preservation of monoclonal antibody (mAb) structure during
production, storage, and shipment is crucial for the efficacy and
safety of mAb-based therapies. Because of their complex structure,
proteins are generally more susceptible to degradation than small-
molecule drugs. Despite extensive efforts undertaken to ensure theantibody; Bis-ANS, 4,40-dia-
salt; BSA, bovine serum al-
ed saline; HRP, horse radish
ody; MW, molecular weight;
w imaging; PBS, phosphate
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®. Published by Elsevier Inc. All rigstability of mAb products, their degradation cannot be fully avoided.
One of the most common mAb degradation products is aggregates.1
Aggregation can be induced by multiple stress factors the product
might be exposed to, such as pH shift, UV exposure, agitation, or
elevated temperature.2,3 Aggregates usually appear in a variety of
sizes and structures, and their presencemay have different biological
consequences.2-4 Multiple studies have shown that mAb aggregates
increase the risk of antidrug antibody (ADA) formation, but the
immunogenic potential differs for aggregates obtained via distinct
stress conditions.5-8 Formation of ADA may lead to altered bioavail-
ability of the mAb and decreased efficacy and safety.9,10 However,
despite years of investigations, it still remains poorly understood
how mAb aggregates may contribute to the ADA triggering and
which feature, or set of features, determines whether aggregates will
be immunogenic or not. A possible relation between aggregate size
and immunogenicity has recently been investigated by several
groups.6,7,11-13 Depending on the study, the most immunogenic ag-
gregates were found in the nanometer or micrometer range, but
aggregate features other than size are most likely also important.14hts reserved.
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dimers have received less attention than submicron- and micron-
size aggregates with respect to their possible immunogenicity.
However, as the simplest mechanisms for bulk aggregation start
with self-assembly of 2 monomers, one may expect dimers to be
one of themost abundant aggregates in high-quality mAb products.
Indeed, dimers are commonly found in commercially availablemAb
drugs.15-17 Importantly, as mAbs are used in relatively high doses
reaching hundreds of mg per injection,1 even a small content of
dimers in a formulation may result in a considerable dose (some-
times up to the mg range) of dimers being administered. Whereas
the efficacy of treatment most likely will not be affected by the
presence of a few percent of dimers in a formulation, the same
cannot be assumed for immunogenicity. The impact of mAb dimers
on immunogenicity has not been studied sufficiently. To our best
knowledge, there is only one report published in which the
immunogenicity of dimers was assessed.6 The overall suggestion
emerging from this article is that dimerization, if not accompanied
by chemical modifications of mAb by UV-induced oxidation, does
not increase the immunogenicity risk. However, further studies are
necessary to investigate whether this finding holds true for
different mAbs and types of dimers.
In our recent study, we showed that submicron-size aggregates
of a monoclonal murine IgG1 (mIgG1) obtained by combination of
low pH, elevated temperature, and stirring stresses were more
immunogenic than oligomers and micron-size particles obtained
under these stress conditions upon subcutaneous (SC) adminis-
tration.13 This aggregation protocol did not allow us to isolate stable
dimers in quantities sufficient for in vivo testing. The aim of the
present study was to investigate the immunogenicity of mIgG1
dimers upon SC administration in a mouse model. To induce
dimerization, the mIgG1 was subjected to low pH or elevated
temperature, that is, individual stress conditions from the protocol
used in our previous study, or to UV irradiation. Dimers have been
isolated via size-exclusion chromatography (SEC), thoroughly
characterized and injected into Balb/c mice according to the
treatment regimen used previously.13 The immunogenicity was
assessed by measuring follicular T cell accumulation in lymph
nodes and spleens and by measuring the ADA response.
Material and Methods
Monoclonal Antibody
Recombinant murine IgG1 (pI: 6.8) formulated at 18.8 mg/mL in
histidine buffered saline (HBS; 25 mM histidine, 150 mM NaCl, pH
6.0) was provided by MedImmune and used as a model mAb.
Generation and Fractionation of Dimers
Three distinct stress conditions were used to generate dimers.
For the pH and temperature stresses, the mIgG1 was diluted with
HBS supplemented with 5% sucrose to a concentration of 2 mg/mL.
Aggregation-inducing experiments were performed in 1.5-mL
Eppendorf tubes, with 0.4 mL of mIgG1 solution per tube. The pH
stress was induced by adding 1 M HCl to obtain a pH of 2.5 and
leaving the acidified sample at ambient temperature for 1 h. After
bringing the pH back to 6 with 1 M NaOH, 20 tubes of stressed
mIgG1 were pooled and the total volume of the solution was
reduced to ca. 1 mL by using a VivaSpin® centrifugal concentrator
(Sartorius Stedim Biotech GmbH, Goettingen, Germany). For the
temperature stress, 1.5-mL Eppendorf tubes containing 0.4 mL of
mIgG1 solution per tube were incubated at 65C for 10 min in an
Eppendorf Thermomixer (Eppendorf, Hamburg, Germany). Next,
the tubes were cooled down at 4C for 10 min and the content of 48tubes was pooled for volume reduction as described previously. For
the UV stress, 3 mL of the undiluted mIgG1 in a 3-mL Schott FIOLAX
drug vial (Schott AC, Mainz, Germany) was exposed to UV-VIS light
(irradiance energy 10.68 W/m2) for 96 h in a light chamber (Powers
Scientific Inc., Warminster, PA) at 23C. The fractionation of pH- and
temperature-stressed samples was performed directly after stress-
ing. The UV-stressed material was aliquoted into 1.5-mL vials, 1 mL
per vial, and stored at 80C before being processed.
The dimers and monomers subjected to stress conditions were
isolated via SEC on an Agilent 1200 system (Agilent Technologies,
Palo Alto, CA) equipped with an autoinjector and a fraction collector.
Fractions were separated on a HiLoad Superdex 200 PG column (GE
Healthcare, Buckinghamshire, UK). Before fractionation the stressed
protein solutions were centrifuged at 18,000 g at 4C for 10 min.
Next, 0.9 mL of supernatant was injected onto the column, HBS was
used asmobile phase, and the flow rate was 1mL/min. One-millilitre
fractions were collected between 45 and 75 min of separation, and
fractions containing dimers and monomers were identified on the
basis of absorbance at 280 nm and pooled (see Supplementary
Fig. S1). The 3 different dimer-enriched products obtained are
referred to as “pH dimer,” “Temp dimer,” and “UV dimer.”Monomers
subjected to stress conditions and purifiedwith SEC are referred to as
“pH monomer,” “Temp monomer,” and “UV monomer.” On frac-
tionation, all isolated samples were stored at80C before use. After
thawing, the samples were centrifuged at 18,000 g, 4C for 30 min
to remove submicron- and micron-size particles that might have
been formed during this freeze-thawing cycle.
The positive control, referred to as “supernatant,” containing
mainly submicron-size particles, was prepared freshly before each
injection as described previously by Kijanka et al.13 (see
Supplementary Figs. S2 and S3 for details about the supernatant
composition).
The protein concentration of all dimeric and monomeric species
was calculated from the area under the respective peaks obtained
during the SEC analysis described in Section Characterization of
Dimers. Samples were screened for endotoxin contamination
with the Pierce® LAL Chromogenic Endotoxin Quantitation Kit ac-
cording to the manufacturer’s protocol (Thermo Fisher Scientific,
Rockford, IL). The measured endotoxin levels were below 0.02 EU/
injected dose, which is below the endotoxin limit for injectable




SEC was used to quantify the content of monomers, dimers, and
oligomers in isolated fractions. Ten microliter of each sample was
analyzed on an Agilent 1200 system (Agilent Technologies) equip-
ped with an autoinjector, an absorbance detector, and a multiangle
laser light scattering Dawn Helios detector (Wyatt Technology,
Dernbach, Germany). A MabPac SEC-1 column (Thermo Fisher Sci-
entific, Rockford, IL) was used for separationwith HBS as an eluent.
Samples were separated for 20min at a flow rate of 0.2mL/min. The
protein peaks were detected at 280 nm, and the MW of the eluting
material was calculated on the basis of multiangle laser light scat-
tering data in the Astra V 5.3.4.20 software (Wyatt Technology).
Dynamic Light Scattering
Malvern Zetasizer Nano ZS (Malvern, Herrenberg, Germany)
equipped with a 633-nm He-Ne laser operating at an angle of 173
was used for dynamic light scattering analysis. A 100 mL of each
fraction in a polystyrene micro cuvette (Brand, Wertheim, Ger-
many) with a 10-mm path length was analyzed at 25C with an
automatic attenuation, run duration, and number of runs. Data
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mean Z-average diameter (Zave) and polydispersity index (PDI) of 4
representative dimer batches are reported.
Nanoparticle Tracking Analysis
Submicron size particles (size range 0.1 mm-1 mm) in all isolated
samples were counted and sized with a NanoSight LM20 (Nano-
Sight, Amesbury, United Kingdom), equipped with a sample
chamber with a 640-nm laser and a syringe pump. Before analysis
all samples were diluted 10 fold in HBS. The measurement was
performed for 90 s with manual adjustment of shutter and gain.
Each sample was measured 3 times. The data was acquired and
analyzed by the NTA 2.3 software (NanoSight). The data for all 8
batches of dimers used for injections are reported.
Micro-Flow Imaging
The number of micron-size particles (size range 1 mm-100 mm)
was determined by using an micro-flow imaging (MFI) DPA4100
series A system (ProteinSimple, Santa Clara, CA) operating at high
magnification (14). A silane-coated 100-mm flow cell (Pro-
teinSimple) was used for all measurements. A sample (10-fold
diluted with HBS) of 0.2 mL was analyzed at a flow rate of 0.17
mL/min. Eachmeasurement was performed in duplicate. Datawere
acquired by the MFI View software, version 6.9, and analyzed with
MVAS, version 1.2, (ProteinSimple). The data for all 8 batches of
dimers used for injections are reported.
Sodium Dodecyl Sulfate Polyacrylamide Gel Electrophoresis
One microgram of protein from each fraction was separated on
4%-15% Mini-Protean® TGX™ pre-cast gel (Bio-Rad Laboratories
B.V., Veenendaal, The Netherlands). A Laemmli sample buffer (Bio-
Rad Laboratories B.V.) with or without a b-mercaptoethanol (Bio-
Rad Laboratories B.V.; final concentration 355 mM) was used.
Samples were incubated at 95C for 5min before loading on the gel.
The electrophoresis was performed with a Bio-Rad Mini-Protean
module and 25 mM Tris, 192 mM glycine, 0.1% sodium dodecyl
sulfate, pH 8.3 (Bio-Rad Laboratories B.V.) as a running buffer.
Separation was initiated with electrophoresis at 80 V for 10 min,
followed by 120 V for 50 min. The MW was estimated on the basis
of Spectra™ Multicolor High-Range Protein Ladder (Thermo Fisher
Scientific) and Precision Plus Protein™ All Blue Standards (Bio-Rad
Laboratories B.V.). Bands were visualized with a Silver Stain Plus kit
(Bio-Rad Laboratories B.V.) according to manufacturer’s protocol.
The images of gels were acquired with a GS-900 densitometer (Bio-
Rad Laboratories B.V.) and the Image Lab v.5.2.1 software (Bio-Rad
Laboratories B.V.). The Image Lab software was also used for band
analysis and calculation of percentage of covalent dimers in the
injection solutions.
Western Blotting and Dot Blotting
For Western blot analysis, 0.1 mg of protein of each fraction was
separated by sodium dodecyl sulfateepolyacrylamide gel electro-
phoresis (SDS-PAGE) under nonreducing conditions as described
previously. Next, SDS-PAGE gels were blotted onto a supported
nitrocellulose sheet (Bio-Rad Laboratories B.V.) with a Bio-RadMini
Trans-Blot electrophoretic transfer cell and 25 mM Tris, 192 mM
glycine and 20% methanol, pH 8.3 as a running buffer. Membranes
were blocked overnight at 4Cwith 2% bovine serum albumin (BSA)
in phosphate buffered saline (PBS) supplemented with 0.05%
Tween 20 (PBST). Next, the blots were incubated for 1 h at ambient
temperature with horse radish peroxidase (HRP)elabeled anti-
mouse total IgG, IgG1, IgG2a (Southern Biotech, Birmingham, AL),
or specific anti-mIgG1 polyclonal antibody purified from sera of
rabbits immunized withmIgG1 by Covance (Denver, CO), all diluted
2000-fold in PBST. Then, the membranes incubated with HRP-Abswere washed 3 times with PBST, followed by 2 PBS washes, and
developed with 3-amino-9-ethylcarbazole chromogenic substrate
(Sigma-Aldrich Chemie B.V., Zwijndrecht, The Netherlands) ac-
cording to the manufacturer’s protocol. The membrane incubated
with rabbit anti-mIgG1 was washed 3 times with PBST and then
incubated for 1 h with peroxidase-labeled anti-rabbit Ab (Thermo
Fisher Scientific), diluted 2000-fold in PBST. Finally, the membrane
was washed and developed with 3-amino-9-ethylcarbazole chro-
mogenic substrate.
Far-UV Circular Dichroism Spectroscopy
For far-UV circular dichroism (far-UV CD), samples in HBS were
buffer-exchanged into 10mMphosphate buffer, pH 7.2 with dialysis
using 0.5-3 mL Slide-a-Lyzer™ dialysis cassettes (Thermo Fisher
Scientific, Rockford, USA). Next, the protein concentration of all
mIgG1 samples was adjusted to 0.1 mg/mL according to their
absorbance at 280 nm. The CD spectrawere collected with a Jasco J-
815 CD spectrometer (Jasco International, Tokyo, Japan) at 25C. A
quartz cuvette with a path length of 0.2 cm was used. The CD
spectra were collected from 190 nm to 250 nm at a speed of 100
nm/min, a data pitch of 0.2 nm, a response time of 8 s, and a
bandwidth of 1 nm. For each sample, 5 accumulations were
collected. Acquired spectra were smoothed with GraphPad Prism®
v 5.02 (GraphPad Software, Inc., La Jolla, CA) as described previ-
ously13,19 and background corrected for the baseline spectrum of
phosphate buffer. A mean residue ellipticity ([q] mean residue
weight [MRW]) was calculated according to Kelly et al.,20 using a
MRWof 112.35 (MRW¼M/N 1, where M is a molecular mass, i.e.,
148300 Da, and N is the number of amino acid residues of mIgG1,
i.e., 1320).
Fluorescence Spectroscopy
The fluorescence emission spectra of isolated fractions were
measured with a steady-state fluorimeter FS900 (Edinburgh In-
struments Ltd., Livingston, UK) equipped with a plate reader. All
measurements were performed on 96-well, black, flat-bottom,
polystyrene plates (Greiner Bio One, Alphen aan den Rijn, the
Netherlands). A volume of 200 mL of each 0.1 mg/mL sample was
used. The intrinsic tryptophan (Trp) fluorescence was recorded
from 310 to 400 nm on excitation at 295 nm. The slits of 3 nm, a
dwell time of 1 s, and steps of 0.5 nmwere used. The final spectrum
was obtained by a cumulative addition of 3 scans. All spectra were
first smoothed as described previously, and then background cor-
rected for the spectrum of the HBS.
Next, 4,40-dianilino-1,10-binaphthyl-5,50-disulfonic acid dipo-
tassium salt (Bis-ANS; Sigma-Aldrich B.V.) was added to each
fraction to a final concentration of 1 mM. The Bis-ANS was excited at
385 nm, and the fluorescence emission was recorded from 410 nm
to 600 nm with 1-nm steps and a dwell time of 1 s. The excitation
and emission slits were both set to 5 nm, and a cumulative addition
of 3 scans for each spectrum was collected. The obtained spectra
were smoothed, and buffer corrected as described previously.
Tryptic Peptide Mapping Using Liquid Chromatography Coupled
With Mass Spectrometry
Potential post-translational modifications and stress-induced
chemical degradation were assessed by tryptic digest peptide
mapping of all samples used in the animal experiments. Denatur-
ation and reduction of 100 mg protein (100 mL protein samples at 1
mg/mL) were initiated by addition of 200 mL of 8 M guanidine, 130
mM Tris, 1 mM EDTA, pH 7.6, and 10 mL of 500 mM dithiothreitol
(Thermo Fisher Scientific). Next, the samples were incubated at
37C for 30min. The samples were then alkylatedwith the addition
of 25 mL of 500 mM iodoacetamide (G-Biosciences, St. Louis, MO)
and incubation at ambient temperature for 30 min while protected
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100 mM Tris, pH 7.6 by centrifugal filtration with a 10-kDa MW
membrane (Millipore Sigma, St. Louis, MO) and digested at 37C for
4 h by using 5 mg of trypsin. The reaction was quenched with 4%
trifluoroacetic acid, and samples were collected for analysis.
Peptides were separated on a Waters Acquity UPLC systemwith
an autosampler and tunable UV detector (Waters Corporation,
Milford, MA) equipped with a BEH300 C18 column (1.7 mm, 2.1 
150 mm; Waters Corporation). Peptides were eluted from the col-
umn by using a gradient from 100% to 65% mobile phase A (0.02%
TFA in water, mobile phase B was 0.02% TFA/acetonitrile) at a flow
rate of 0.2 mL/min and total elution time of 78 min. Eluted peptides
were detected by UV absorbance at 220 nm and analyzed by a
Waters Synapt G2 QTOF mass spectrometer (Waters Corporation).
Data were acquired and analyzed using the Waters UNIFI and
MassLynx software (Waters Corporation).
Estimation of Protein Mass Within Different Size Ranges of
Aggregates
SEC, nanoparticle tracking analysis (NTA), and MFI were used to
estimate the mass of protein in different size ranges for each
enriched fraction as described previously.13,21-23 In short, the mass
of mIgG1 fragments, monomers, and oligomers was calculated
from the peak areas under the curve in the SEC analysis. The mass
of protein submicron- and micron-size particles was calculated on
the basis of NTA andMFI data according to the formula proposed by
Barnard et al., that is, M ¼ d*V*n*p, where d is the density of the
protein (1.4 mg/mL), V is the volume of particles per size bin (1 nm
for NTA and 0.25 mmMFI), n is the number of particles per size bin,
and p is the fraction of the particle volume (V) occupied by protein
(assumed to be 0.75).21
Animal Study
Mice
BALB/c mice aged 6-8 weeks were obtained from Charles River
Laboratory (L’Arbresle Cedex, France) and kept in standard cages
with access to food and water (acidified) ad libitum. All testing was
conducted with approval of the Animal Ethic Committee of Leiden
University Medical Center (protocol number 14096).
Animal Experiments
A total number of 128 mice were divided into 8 groups (n ¼ 16)
of which 3 were treated with different dimer-enriched fractions, 3
with the corresponding stressed monomers, one with unstressed
mIgG1 (referred to as “unstressed”) as a negative control, and one
with supernatant (positive control). Mice were injected subcuta-
neously between the shoulders, twice per week for 8 weeks with 10
mg of protein diluted in endotoxin-free HBS. The basal level of ADA
was determined for each mouse in blood collected from the sub-
mandibular vein before the first injection. From each mouse, blood
was collected every second week. Four mice per group were
sacrificed 1 week after the second injection (day 10 of the experi-
ment), and the remaining animals were sacrificed 2 weeks after the
last injection (day 65). The draining lymph nodes (LNs), that is,
brachial and axillary LNs, and spleens were extracted after eutha-
nasia for ex vivo analysis.
Blood was collected into the MiniCollect® Serum Z separator
tubes (Greiner Bio-One). Serum was isolated by centrifugation
(3000 g, 10 min, 4C), collected into storage tubes (Thermo Fisher
Scientific), and kept at 80C for analysis.
Antidrug Antibody Detection
The ADA screening was performed with a bridging ELISA as
described previously.13,24 A biotinylated and digoxigeninylatedmIgG1 were used as capture and detection reagents, respectively.
Dulbecco's PBS (Thermo Fisher Scientific) supplemented with 0.5%
BSA (Sigma-Aldrich Chemie B.V.) was used as assay buffer, and
polyclonal rabbit anti-mIgG1 antibody was used as the assay-
positive control. Between detection steps, plates were washed 8
times with PBST. Samples and polyclonal rabbit anti-mIgG1 ADA
assay controls (spiked in pooled BALB/c sera) were diluted at a
minimum dilution of 1/100 in assay buffer and incubated overnight
with capture and detection reagents (1.25 mg/mL each). On the
following day, samples were transferred into wells of a
streptavidin-coated plate (Thermo Fisher Scientific) and incubated
at room temperature for 1 h to capture the ADA-bridged complexes.
After a wash, a peroxidase-labeled anti-digoxigenin antibody
(Jackson Immunolabs, Suffolk, UK)was added into thewells and the
resulting mixtures were incubated for 1 h and washed away. The
QuantaRed™ Enhanced Chemifluorescent was used as the HRP
Substrate Kit (Thermo Fisher Scientific). The fluorescence was
excited at 570 nm, and emission at 585 nm was measured with a
Tecan Infinity plate reader (Tecan Group Ltd., M€annedorf,
Switzerland).
The signal of each sample was normalized against background
signal for pooled negative BALB/c sera (Bioreclamation, Westbury,
NY). A cutoff point was defined as the upper 95th percentile of the
signal-to-background ratios (S/B's) from basal blood samples (n ¼
84). Serum was classified as positive if the S/B was equal to or
higher than the cutoff point. All samples found to be positive in the
screening assay were tested in a confirmatory assay in which the
unlabeled mIgG1 was used as a competitor during the overnight
incubation step.13
Follicular T Helper Cell Detection
A single cell suspension was prepared by pressing spleens and
LNs through a Falcon® 70-mm cell strainer (Corning, Amsterdam,
The Netherlands). Next, red blood cells present in splenocytes
after the suspension were lysed with ACK lysis buffer (Thermo
Fisher Scientific) according to manufacturer’s protocol. Approxi-
mately 100,000 cells were suspended in 100 mL of cold PBS with
1% BSA and stained on ice with anti-CD3-FITC, CD4-eFluor450,
CXCR5-PeCy7, and PD1-PE Abs (all eBioscience, Vienna, Austria),
diluted according to manufacturer’s protocol. After 40-min incu-
bation, cells were spun down (300 g) and unbound detecting re-
agents were removed by 2 times washing with PBS with 1% BSA.
After the last wash, cells were fixed with 1% polyformaldehyde in
PBS and analyzed with a FACS Canto II flow cytometer (BD Bio-
sciences, Vianen, The Netherlands). The obtained data were
analyzed with FlowJo® X (FlowJo LLC, Ashland, OR) using the
gating strategy described previously to quantify follicular T helper
(TFH) cells.13
Statistical Analysis
The potential difference between ADA responses upon injection
of different fractions was assessed with one-way ANOVA with
Dunnet’s multiple comparison test. Calculations were performed in
the GraphPad Prism® v.5.02 software.
Results
Composition of Fractions Enriched in Dimers
The mass of mIgG1 in the form of monomers, dimers, or larger
aggregates was estimated on the basis of SEC, NTA, and MFI data
(Fig. 1). The composition of all dimeric fractions and the corre-
sponding monomeric counterparts is shown in Figure 2. All dimer-
enriched fractions were composed of at least 50% dimers. The
highest dimer content (85%) was found in UV dimers, followed by
Figure 1. Size distribution of the samples used for immunogenicity assessment. (a) Representative SEC chromatograms recorded at A280. (b) Average concentrations of submicron-
size (NTA) particles. (c) Average concentrations of micron-size (MFI) particles. The bars represent the average values (þSD) for 8 batches of each sample.
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fractions contained also significant amounts of monomers, ranging
from 13% in UV dimers to 40% in Temp dimers. Oligomers
accounted for 14% of pH dimers, 4% of Temp dimers, and 1.9% of UV
dimers. The amount of submicron- and micron-size particles in all
dimer samples was negligible (all estimated to be below 1.5%).
Unstressed control and all fractions containing stressed monomersFigure 2. Composition of injected samples expressed as a percentage owere indeed composed of mainly monomers (>96%). Only pH
monomers contained a small amount of dimers (ca. 3%). In contrast,
the supernatant primarily consisted of submicron-size particles
with small amounts of oligomers and micron-size particles (see
Supplementary Fig. S2).
According to the dynamic light scattering analysis, the Zave of
Temp monomers and UV monomers was highly similar to that off injected dose (%ID) calculated on the basis of SEC, NTA, and MFI.
Table 1
Summary of the Results of Dynamic Light Scattering Measurements (Average ± SD;
n ¼ 4 Batches)
Sample Dynamic Light Scattering
Zave (nm) PDI
Unstressed 11.7 ± 0.8 0.09 ± 0.06
pH Monomer 14.0 ± 1.1 0.23 ± 0.04
pH Dimer 20.5 ± 3.8 0.20 ± 0.04
Temp Monomer 11.3 ± 0.3 0.06 ± 0.04
Temp Dimer 21.3 ± 5.3 0.24 ± 0.07
UV Monomer 11.4 ± 0.2 0.08 ± 0.02
UV Dimer 22.9 ± 4.2 0.24 ± 0.04
G. Kijanka et al. / Journal of Pharmaceutical Sciences xxx (2019) 1-96unstressed mIgG1 (ca. 11.5 nm, see Table 1). The measured Zave of
pH monomers was slightly larger, 14 nm, probably due to the small
amount of dimer in the pH monomer fraction or the presence of
expanded monomers or both, as has been observed before for pH-
stressed IgG.19 The Zave of all dimer-enriched fractions was very
similar (20-23 nm). It has to be noted that the PDI of unstressed,
Temp monomers, and UV monomers was below 0.1, indicating
highly homogenous composition of these fractions. The PDI of all
other solutions was within the range of 0.2-0.25.
Structural Characterization
The secondary structure of the mIgG1 in the different samples
was assessed by far-UV CD spectroscopy. As depicted in Figure 3,Figure 3. Spectra resulting from structural characterization of mIgG1 samples with far-U
fluorescence (lower plots). Each spectrum is an average of 3 independent experiments.only minor alterations in the far-UV CD spectra when compared
with unstressed control were observed, indicating that the mIgG1
secondary structure was highly preserved after stress treatment
and fractionation of dimers and monomers. All spectra are typical
for IgG1 dominated by beta-sheet.20,25,26
Possible alteration in tertiary structures was determined by
measurement of intrinsic Trp fluorescence (Fig. 3). The spectra of
pH- and temperature-stressed samples were very similar to the
spectrum of unstressed control. However, a minor shift in the
emissionwavelength maximum (lmax) from 346 nm for unstressed
control to 347.5 nm for pH dimers and 347 nm for Temp dimers was
recorded. The lmax of pH monomers was 346.5 nm, and for Temp
monomers, 346 nm. In contrast, the fluorescence intensity of UV-
treated samples was almost 2 times lower than that of unstressed
control. The shift in lmax for both UV dimers and UVmonomers was
minimal (lmax of 346.5 nm and 345.5 nm, respectively).
Additional assessmentof possible alteration in tertiary structures
was done by adding extrinsic, hydrophobic probe (Bis-ANS) to all
fractions and measuring its fluorescence. As shown in Figure 3, the
fluorescence of Bis-ANS in the presence of Unstressed control, UV
dimers, and all monomeric samples was similarly low, indicating
lack of exposure of new hydrophobic patches on the mIgG1 surface
after applying stress and fractionation. In contrast, in the presence of
pHdimers and Tempdimers, the Bis-ANSfluorescencewas elevated.
In addition to spectrofluorometric measurements, all fractions
were analyzed with SDS-PAGE and Western blotting (Fig. 4). SDS-
PAGE revealed that 58% of all dimers found in UV dimers and 38%V CD (upper panels), intrinsic Trp fluorescence (middle plots), and extrinsic Bis-ANS
Figure 4. SDS-PAGE (a) and Western blot (b) analysis of injection solutions.
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jority of the dimers in pH dimers were not covalent (only 7.6% of the
dimers were covalently linked). On treatment with reducing agent,
all dimers in pH dimers and Temp dimers were dissociated, indi-
cating that these dimers were mediated by disulfide bridge for-
mation. In UV dimers, several bands with apparent MWs higher
than 50 kDa, that is, mAb’s heavy chain weight, were detected,
pointing to other chemical modifications besides disulfide bridges.
In Western blot analysis, all species of all samples, both mono-
meric and dimeric, were recognized by a panel of polyclonal anti-
bodies used for mIgG1 detection, similarly to unstressed control,
indicating the preservation of native epitopes in the stressed
samples (Fig. 4b).
Liquid Chromatography Coupled with Mass Spectrometry
Tryptic peptide mapping by liquid chromatography coupled
with mass spectrometry analysis revealed that all stress conditions
applied to induced dimers resulted in some chemical modifications
of bothmonomer and dimer fractions. UnstressedmIgG1 contained
low levels of oxidized and deamidated amino acid residues in the
heavy chain (Table 2). The pH stress not only increased the level of
existing deamidation sites but also led to deamidation of aspara-
gine 74 and 84. In contrast, UV stress did not change deamidation
levels but increased the level of oxidation and led to new oxidation
sites in both heavy (Trp 47 and 110) and light chains (Trp 37 and
methionine 49). Temperature treatment led to increased oxidation
and deamidation at existing and new sites.
Immunogenicity
The immunogenicity of the different dimers and their stressed
monomeric counterparts was assessed by detecting ADA in bloodand determination of TFH cells activation in LNs and spleens.
Administration of stressedmonomers or dimers did not trigger ADA
formation in any of the mice, similarly to unstressed control,
throughout the entire time course of the experiment. Figure 5a
shows the results for the last time point (day 65). Moreover, no
significant change in the number of TFH cells in LNs or spleens at any
time point of treatment was detected (Fig. 5b and Supplementary
Fig. S4). In contrast to dimer-enriched samples, the supernatant
triggeredADA in5of 12mice, in linewithour previous publication.13
Moreover, the number of TFH cells in spleens extracted on day 65
frommice treatedwith supernatantwas significantly higher than in
mice receiving unstressed control (p < 0.05).
Discussion
By definition, an aggregate is an assembly of protein molecules
of MW higher than that of the physiologically active unit. For IgGs,
the smallest possible aggregate is a dimer, that is, an assembly of 2
IgG molecules. Naturally occurring dimers of IgG1 and IgG2 sub-
types have been found in serum.27 Moreover, dimers have been
identified in several commercial mAb products.15-17 Despite their
small size, dimers display diverse characteristics, as demonstrated
in several studies. In a study by Remmele et al., dimers of eprazu-
mab, a humanized IgG1, were found to be mostly covalent, bio-
logically active, and with a highly preserved mAb secondary
structure. The dimerization was found to be facilitated via Fab:Fab,
Fc:Fc, and Fab:Fc interactions.15 Similarly, dimers of another hu-
manized IgG1, palivizumab, were also found to be partially cova-
lent, fully active and of native structure.16 However, in contrast to
the eprazumab study, only interactions between Fab:Fab and Fab:Fc
were identified. In another report describing structural character-
ization of dimers, Paul et al. compared artificially created and
Table 2
Results of Peptide Mapping With Liquid Chromatography Coupled With Mass Spectrometry Analysis of the mIgG1 Fractions
Sample % Peak Area
Oxidation
Heavy Chain Light Chain
M34, W36 W47 W110 M255 W37 M49
Unstressed 0.9 ND ND 1.1 ND ND
pH Monomers 2.1 ND ND 1.5 ND ND
pH Dimers 1.9 ND ND 1.7 ND ND
Temp Monomers 5.1 ND 1.6 6.4 ND 3.7
Temp Dimers 4.8 ND 2.1 6.1 ND 4.1
UV Monomers 4.3 2.0 1.8 2.8 2.4 1.0
UV Dimers 4.0 2.2 2.3 3.0 1.9 0.9
Sample Deamidation Isomerization
Heavy Chain Heavy Chain
N52N53N54(G) N74(S) N84(S) Q112(G) N387(G)N392N393(Y) D62(S) D108(S)
Unstressed 1.3 ND ND ND 5.1 ND ND
pH Monomers 4.0 1.1 1.4 ND 8.6 ND ND
pH Dimers 5.2 1.1 1.1 ND 7.9 ND ND
Temp Monomers 4.1 1.8 1.5 ND 6.0 ND ND
Temp Dimers 3.7 1.5 1.6 ND 6.3 ND ND
UV Monomers 2.0 ND ND ND 4.5 ND ND
UV Dimers 2.1 ND ND ND 4.0 ND ND
ND, not detected.
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process-related stress or UV irradiation, interactions between
Fab:Fab were identified. In contrast, pH stress led to formation of
dimers via Fab:Fab or Fab:Fc bonds. All dimers differed in potency
and Fc receptor binding affinity. The potency of pH dimers was
similar to that of unstressed control, but the potency of UV and
process-related dimers was strongly reduced. All dimers showed
increased affinity to an Fc receptor. In another study, dimers of 3
humanized IgG1s were investigated.29 All tested IgG1s tended to
form predominantly 2 distinct forms of dimers, referred to as
“compressed” and “elongated” types. Both forms of dimers were
formed exclusively via Fab:Fab interactions. The binding between 2
antigen binding sites resulted in an elongated, fiber-like form of
dimer. Both covalent and noncovalent links were identified in this
type of dimers. In contrast, the compressed, globular dimers were
created by noncovalent interaction of constant regions of Fab do-
mains or hinge regions.
The result of physicochemical characterization of dimers used in
this study is in accordance with observations described in the
literature. Mainly noncovalent pH dimers and mostly covalent UVFigure 5. In vivo assessment of immunogenic potential of dimer-enriched samples. (a) ADA p
after the last mIgG1 administration (day 65). Each dot represents the result for individualdimers have been described for another mAb.28 Also, covalent,
nonreducible bonds have been previously observed for UV-treated
mAbs.5,28 Moreover, the observation that dimerization did not
measurably affect the secondary structure of mIgG1, even when
accompanied by chemical modifications, corresponds with the re-
sults of Paul et al.28 In our present study, the analysis of intrinsic Trp
fluorescence suggested no major alterations in tertiary structure of
all dimer types. Lowermaximum fluorescence of Trp in UV-stressed
samples originated most likely from its oxidation (leading to a
decreased number of intact Trp residues) rather than from changes
in Trp's local environment.30 This is in line with the lack of increase
of Bis-ANS fluorescence in presence of UV dimers. Interestingly,
despite the apparent high level of preservation of secondary and
tertiary structures for pH dimers and Temp dimers, the Bis-ANS
fluorescence in presence of these solutions was elevated. This
observation might indicate that some hydrophobic patches on pH
dimers and Temp dimers have been exposed during dimerization.
However, it cannot be excluded that increased Bis-ANS fluores-
cence in presence of pH dimers and Temp dimers was due to
oligomers that were co-purified with these dimers (14% of pHroduction. (b) Activation of TFH in spleen. Both measurements were performed 2 weeks
mouse. *p < 0.05.
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matograms of crude pH and temperature-stressed mIgG1 show
that, in contrast to UV irradiation, significant amount of trimers and
higher-MW oligomers have been created during aggregation (see
Fig. S1). The increase in Bis-ANS fluorescence suggests that
these oligomers might contain conformationally altered mIgG1
similarly to submicron-size particles found in supernatant (see
Supplementary Fig. S3).
There is very limiteddata available regarding the relationbetween
dimerization of mAb and potentially increased risk of immunoge-
nicity. To our best knowledge there is only one manuscript available
tackling the problem of immunogenicity of dimers. Bessa et al.6
investigated the relation between human IgG1 aggregate size (up to
oligomers) and immunogenicity. In this study aggregates were
induced by low pH, UV exposure and “process related” stresses and
separated into fractions enriched in monomers, dimers and higher-
MW oligomers. Among all tested dimers, only UV-irradiated ones
induced higher ADA levels than unstressed monomeric control in
transgenic mice. These data led to the conclusion that a combination
of aggregation and chemical modifications is required for ADA for-
mation. Our data partially correspondwith this report, as none of the
tested dimers, even those carrying higher levels of post-translational
modifications thanunstressed control,weremore immunogenic than
unstressed control. Thus, our data strongly support the hypothesis
thatdimerization isnot sufficient to increase the riskofADAresponse.
This makes immunologically sense, as to our knowledge there is no
evidence that native IgA (dimeric) or IgM (pentameric) is more
immunogenic than (monomeric) IgG, although head-to-head com-
parisons are lacking. In contrast, the immunogenicity of our positive
control (submicron size aggregates) is in qualitative alignment with
the vast literature about nanoparticulate antigens, which in general
are much more immunogenic than antigens free in solution.31,32
Interestingly, in our hands, even UV-irradiated dimers were not able
to trigger ADA formation. This difference between our and Bessa’s
results could be explained by differences between the proteins,
mouse models and treatment regimens used, or the extent of chem-
ical modifications or combination of all those factors. It has been
shown that the choice of mouse model and treatment regimen
significantly influences the ADA production.7,33,34 Our data show lack
ofADA formationupon administration of dimers, but a clear response
to submicron-size aggregates.These results indicate thatdimers, even
chemically modified ones, may be of lower ADA formation risk than
submicron particles composed of chemically unmodifiedmIgG1. This
suggests that aggregate size by itself might be a relevant factor
influencing the immunogenicity risk, in line with the conclusion of
earlier studies.6,7,11-13
Because dimers are a significant type of mAb aggregates present
in commercially available products, insight into the potential
immunogenicity of dimers is highly relevant from a clinical point of
view. According to data presented in this article, dimerization does
not appear to increase the risk of ADA formation.
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